… from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545. About … candidates and the timing thereof, including those in our innovation pipeline, statements regarding release of clinical …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators in Q3